<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"
					xmlns:content="http://purl.org/rss/1.0/modules/content/"
					xmlns:wfw="http://wellformedweb.org/CommentAPI/"
				  >
<channel>
<title>TAPA Medical Bulletins (TNPA.COM)</title>
<link>http://www.tnpa.com/news/rss/</link>
<description><![CDATA[TAPA Medical Bulletins news feed brings you up-to-date industry and member news from the Tennessee Academy of Physician Assistants.]]></description>
<language>en-us</language>
<managingEditor>kmoffat@tnpa.com (Katherine Moffat, Executive Director)</managingEditor>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<image><title>TAPA Bulletin</title>
<link>http://www.tnpa.com/news/rss/</link>
<url>http://www.tnpa.com/news/rss/tapalogo.jpg</url>
</image>
<item>
<title>Vialipro Dietary Supplement: Recall- Undeclared Drug Ingredient </title>
<link>http://www.tnpa.com/news/story.php?id=27</link>
<pubDate>Mon, 26 Jul 2010 09:03:19 -0600</pubDate>
<description><![CDATA[ISSUE: Good Health, Inc. is conducting a voluntary recall after an FDA lab analyses found that the product tested from certain batches of Vialipro contain Sulfoaildenafil, an analogue of Sildenafil, an FDA-approved drug used as treatment for male Erectile Dysfunction (ED) making this product an unapproved drug. The undeclared ingredient may pose a threat to the consumer because the interaction of the analogue with some prescription drugs (such as nitroglycerin) may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take other prescription drugs. 

]]></description>
</item>
<item>
<title>Qualaquin (quinine sulfate): New Risk Evaluation and Mitigation Strategy - Risk of serious hematological reactions</title>
<link>http://www.tnpa.com/news/story.php?id=25</link>
<pubDate>Tue, 13 Jul 2010 14:53:36 -0600</pubDate>
<description><![CDATA[ISSUE: Due to continued reports of serious side effects in patients using Qualaquin "off-label" for night time leg cramps, FDA has approved a risk management plan to warn against the use of this drug for such unapproved uses. Qualaquin should not be used for night time leg cramps. Qualaquin use may result in serious and life-threatening hematological reactions, including serious bleeding due to thrombocytopenia, and hemolytic-uremic syndrome/ thrombotic thrombocytopenic purpura, which in some cases may result in permanent kidney damage. In some patients, adverse reactions result in hospitalization and death. ]]></description>
</item>
<item>
<title>Que She Herbal Supplement: Undeclared Drug Ingredients </title>
<link>http://www.tnpa.com/news/story.php?id=24</link>
<pubDate>Tue, 13 Jul 2010 14:52:28 -0600</pubDate>
<description><![CDATA[ISSUE: FDA warned consumers and healthcare professionals that Que She, marketed as an herbal weight loss supplement, contains unlisted and active pharmaceutical ingredients that could harm consumers, especially those with cardiovascular conditions. These active pharmaceutical ingredients also may interact with other medications and result in a serious adverse event. 

]]></description>
</item>
<item>
<title>Arava (leflunomide): Boxed Warning - Risk of Severe Liver Injury </title>
<link>http://www.tnpa.com/news/story.php?id=23</link>
<pubDate>Tue, 13 Jul 2010 14:14:43 -0600</pubDate>
<description><![CDATA[ISSUE: FDA is adding information on severe liver injury to the Boxed Warning of Arava (leflunomide) a drug used to treat rheumatoid arthritis
- to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced. FDA previously required a Boxed Warning stating that leflunomide was contraindicated in pregnant women, or women of childbearing potential who were not using reliable contraception. 
]]></description>
</item>
<item>
<title>Qualaquin (quinine sulfate): New Risk Evaluation and Mitigation Strategy - Risk of serious hematological reactions </title>
<link>http://www.tnpa.com/news/story.php?id=22</link>
<pubDate>Fri, 09 Jul 2010 15:18:03 -0600</pubDate>
<description><![CDATA[ISSUE: Due to continued reports of serious side effects in patients using Qualaquin "off-label" for night time leg cramps, FDA has approved a risk management plan to warn against the use of this drug for such unapproved uses. Qualaquin should not be used for night time leg cramps. Qualaquin use may result in serious and life-threatening hematological reactions, including serious bleeding due to thrombocytopenia, and hemolytic-uremic syndrome/ thrombotic thrombocytopenic purpura, which in some cases may result in permanent kidney damage. In some patients, adverse reactions result in hospitalization and death. ]]></description>
</item>
</channel>
</rss>